Syngene International Limited has announced a strategic strengthening of its board with the appointment of three independent directors. The company said that, based on the recommendation of the Nomination & Remuneration Committee, the Board approved the appointment of Vijaya Chandru and Arun Chandavarkar as Additional Directors (Independent, Non-Executive) for a three-year term ending with the conclusion of the 33rd Annual General Meeting in 2029. It also confirmed the reappointment of Vinita Bali as Additional Non-Executive Director for a one-year period from July 22, 2026 to July 21, 2027. As with such governance steps, the appointments are subject to shareholder approvals. The company also notes that Vijaya Chandru, Arun Chandavarkar and Vinita Bali are not debarred from holding director positions by SEBI or other authorities.
Vijaya Chandru brings a deep-tech, decision-sciences perspective to the board. An academic-entrepreneur with a PhD in Operations Research from MIT, his work spans optimization, geometry, logic and computational biology. He has co-founded multiple ventures and remains engaged with leading research institutions, including IISc and IITs. His background suggests a governance lens that blends cutting-edge science with strategic technology deployment, a dimension many boards seek in today’s innovation-driven biopharma ecosystem.
Arun Chandavarkar joins the board after a long career at Biocon Limited, where he retired as CEO & Joint Managing Director in 2019 following a 29-year tenure. He is credited with guiding Biocon’s transformation journey—from enzymes to a globally recognized biopharma entity—through pivotal IPO activity, R&D and infrastructure investments, and strategic restructurings. His experience across leadership, partnerships and scale-up could offer Syngene valuable perspectives on growth, integration and industry collaboration.
Vinita Bali’s appointment adds a global business leadership profile to Syngene’s governance mix. A former CEO & MD of Britannia Industries, her career spans executive roles at The Coca-Cola Company and Cadbury Schweppes and leadership on international boards, including SATS Ltd, Cognizant Technology Solutions, and Bajaj Auto Limited. As a non-executive director and member of key committees at Syngene, her breadth of experience across consumer and global operations could help shape strategic oversight, risk management and stakeholder engagement for the company’s next phase of growth.